Axa's Nine-Month Performance Driven by Property and Casualty Segment
By Giulia Petroni
AXA said gross written premiums and other revenue rose slightly in the first nine months of the year, boosted by the property and casualty business, and that it is on track to meet its full-year earnings target.
The French insurer said Thursday that gross written premiums and other revenue came in at 78.76 billion euros ($83.25 billion) in the period, up 1% on year from EUR78.02 billion the year earlier. On a comparable basis, the figure was up 2%.
Revenue at AXA's property and casualty business rose 5%, while the life-and-health and asset-management segments both registered a 3% decline.
AXA said it expects to meet its underlying earnings target of more than EUR7.5 billion for the year. It expects some headwinds from higher health claims frequency in the U.K., elevated lapses in Italy, and natural catastrophe activity in the third quarter.
Total debt at year end is expected to remain broadly stable compared with last year, the company said.
Write to Giulia Petroni at giulia.petroni@wsj.com
(END) Dow Jones Newswires
November 02, 2023 13:10 ET (17:10 GMT)
Copyright (c) 2023 Dow Jones & Company, Inc.-
5 Undervalued Stocks to Buy to Play a Little Defense
-
Markets Brief: AI Leaders Excel In Earnings Season So Far
-
What History Tells Us About the Fed’s Next Move
-
What’s Happening In the Markets This Week
-
Alphabet’s New Dividend: What Investors Need to Know
-
Going Into Earnings, Is Palantir Stock a Buy, a Sell, or Fairly Valued?
-
Going Into Earnings, Is Eli Lilly Stock a Buy, a Sell, or Fairly Valued?
-
What’s the Difference Between the CPI and PCE Indexes?
-
After Earnings, Is Tesla Stock a Buy, a Sell, or Fairly Valued?
-
After Earnings, Is GE Aerospace Stock a Buy, a Sell, or Fairly Valued?
-
3 Good Stocks to Buy with Your Tax Refund in 2024 (Or with Any Extra Money)
-
SoFi Earnings: Revenue Growth Slows on Lower Loan Growth and Higher Credit Costs
-
Tesla: Full Self-Driving Approval In China Supports Our View for Deliveries Growth In 2024
-
Philips Earnings: Firm Reaches $1.1 Billion Settlement Agreement
-
AbbVie Earnings: Next-Generation Immunology Drugs Help Offset Humira Biosimilar Pressure
-
Exxon Earnings: Ignore Earnings Shortfall as Long-Term Growth and Improvement on Track